Foundation for Polish Science TEAM TECH Core Facility Plus/2017-2/2 (POIR.04.04.00-00-23C2/17)
Project co-financed by the European Union under the European Regional Development Fund
"Flow-PROSPER – Flow Cytometry Protein Signature Platform for Personalised Therapies"
The aim of the Flow-PROPSER project is to develop advanced flow cytometry protein signature platform for designation of specific sets of protein markers assisting in the development of personalized therapies.
Project funds: 1 498 638 PLN
The goal of the FlowPROSPER project is to develop advanced Flow Cytometry Protein Signature platform and service for the biomedical research and R&D sector, in the field of personalized therapies. Civilization diseases, including cancer, cardiovascular and neurodegenerative diseases, are the major socio-economical burden for societies worldwide. Development of personalized therapies to treat civilization diseases is a current line in the biomedical sector. Also, designing of novel methods and markers to diagnose susceptibility to treatment and effectiveness of the therapy is important. Specifically, we plan to create the advanced multicolor flow cytometry service to analyze the specific protein signatures, which can be used to predict sensitivity to personalized therapies or even monitor the response and efficiency of treatment. This panels can be designed for a broad range of biomedical proof-of-concept, preclinical and clinical studies, in a multiple civilization diseases.
Additional funds dedicated to new research task aimed at fighting the COVID-19 pandemic within the ongoing FlowProsper project awarded (15.06.2020).
With the support of Foundation for Polish Science TEAM TECH Core Facility Plus/2017‐2/2 (POIR.04.04.00‐00‐23C2/17), the following publications was created:
Swatler J, Dudka W, Bugajski L, Brewinska-Olchowik M, Kozlowska E, Piwocka K. Chronic myeloid leukemia-derived extracellular vesicles increase Foxp3 level and suppressive activity of thymic regulatory T cells. Eur J Immunol. 2019 Nov 23. doi: 10.1002/eji.201848051. [Epub ahead of print] PubMed PMID: 31758697
Szymańska E, Nowak P, Kolmus K, Cybulska M, Goryca K, Derezińska-Wołek E, Szumera-Ciećkiewicz A, Brewińska-Olchowik M, Grochowska A, Piwocka K, Prochorec-Sobieszek M, Mikula M, Miączyńska M. Synthetic lethality between VPS4A and VPS4B triggers an inflammatory response in colorectal cancer. EMBO Mol Med. 2020 Jan 13:e10812. doi: 10.15252/emmm.201910812. [Epub ahead of print] PubMed PMID: 31930723.
AWARD FOR KATARZYNA PIWOCKA
Polish Intelligent Development Award 2020 for dr hab. Katarzyna Piwocka
The Intelligent Development Forum and Award are dedicated to new technologies, innovations, inventions and innovative investments related to the transfer of knowledge from the science to business sector. The forum is an event whose goal is to identify the possibilities of commercial use of research results, knowledge and competences of innovators, to learn about the mutual needs and expectations of the business, scientific and social environment, and to promote innovation and investment before potential clients, investors or business partners.
The prize was awarded in the "Future Scientist" category for the implementation of two projects:
- FNP (Foundation for Polish Science) FlowPROSPER - Flow Cytometry Protein Signature Platform for Personalised Therapies
- Bio4Med - Biology for Medicine (International PhD Programme in Biological Bases of Human Diseases) - European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie COFUND grant agreement No 665735
- NCN (National Science Center) - Tunneling nanotubes (TNTs) within the leukemia microenvironment; influence of metabolic remodeling and implications for therapy